🔍

Alpa Laboratories Limited (ALPA)

₹53.46 -4.47% last close, 16 Oct

📊 NSE: ALPA 🏢 Pharmaceuticals - Indian - Formulations 📢 Latest filing: 14 Oct 2026 📝 Analysis written: 13 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Alpa Laboratories' revenue was ₹23.9 Cr (+25.2% year on year, -23.8% on the previous quarter), and net profit ₹1.0 Cr (-91.7% year on year); the operating margin was -16.5%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹23.9	+25.2%	-23.8%
Operating profit	₹-4.0	to loss	to loss
Net profit	₹1.0	-91.7%	-29.0%
EPS (₹)	0.49	-91.2%	-25.8%
Operating margin	-16.5%	—	—

Full quarterly financials → Results calendar →

ALPA delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 49.06% of the ALPA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 61.16%. That is close to its usual level. Turnover was only ₹17 lakh, so a handful of trades can move this figure.

49.06%Delivery, 16 Oct

61.16%Own 20-session average

1.6×Volume vs its average

₹53.46NSE close · -4.47%

Delivery in the last 5 sessions: 54.7% · 55.7% · 86.2% · 75.8% · 49.1%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Alpa Laboratories Submits Reg 74(5) Depository Certificate for Q2 Ended Sep 30, 2026

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 14 Oct 2026, 02:51 PM

Alpa Laboratories Limited has submitted the compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate was issued by Bigshare Services Pvt. Ltd., the company's Registrar and Share Transfer Agent, dated October 9, 2026. It confirms that securities received for dematerialization were processed, mutilated, and cancelled within 15 days of receipt. This is a standard quarterly regulatory compliance filing with no impact on business operations or financials.

Compliance certificate received under Regulation 74(5) of SEBI Regulations, 2018
Quarter ended September 30, 2026 covered in the confirmation
Dematerialization requests confirmed, mutilated, and cancelled within 15 days of receipt
Certificate issued by RTA Bigshare Services Pvt. Ltd. on October 9, 2026

💡 No action required. Investors should track upcoming Q2 FY27 financial results for operational performance.

Alpa Labs Shareholders Approve ₹160 Cr Section 186 Limit and Re-appointment of MD

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 03 Oct 2026, 12:30 PM

Alpa Laboratories announced the voting results of its 38th Annual General Meeting held on September 30, 2026. All 7 resolutions were approved by shareholders with over 99.2% approval. Notably, shareholders passed a special resolution approving loans, guarantees, and investments under Section 186 up to ₹160 crore (material compared to TTM revenue of ₹111 crore and net worth of ₹197 crore). Additionally, the re-appointment of Paresh Chawla as Managing Director for 5 years effective May 28, 2026, was cleared with 99.299% votes.

Special resolution approved for loans, guarantees, and investments under Section 186 up to ₹160 crore (99.295% votes in favor)
Re-appointment of Paresh Chawla as Managing Director for 5 years passed with 99.299% approval
Appointment of Mrs. Radhika Biyani as Independent Director for 5 years approved (99.299% in favor)
Total of 49 shareholders holding 1,21,56,330 shares participated in the e-voting process

💡 Track future quarterly balance sheets and related-party disclosure filings to see how much of the ₹160 crore investment/loan limit is actually deployed.

Alpa Labs AGM Approves Up to Rs 160 Cr Limits Under Section 186, Re-appoints MD

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Sep 2026, 10:07 PM

Alpa Laboratories held its 38th Annual General Meeting on September 30, 2026. Key special resolutions presented included seeking shareholder approval for loans, guarantees, and investments under Section 186 up to Rs 160 crore (relative to net worth of Rs 197 crore). Additionally, shareholders approved the re-appointment of Paresh Chawla as Managing Director for 5 years effective May 28, 2026, and appointed Radhika Biyani as an Independent Director for 5 years.

Shareholders considered authorization for loans, guarantees, and investments up to Rs 160 crore under Section 186.
Re-appointed Paresh Chawla as Managing Director for a 5-year term from May 28, 2026 to May 28, 2031.
Appointed Radhika Biyani as Independent Director for 5 years ending September 30, 2031.
Ratified cost auditor remuneration of Rs 70,000 per year plus out-of-pocket expenses for FY 2026-27.

💡 Track the upcoming voting results filing to confirm final resolution passage and monitor future quarterly filings for any actual utilization of the Rs 160 crore loan/investment envelope.

Alpa Laboratories Appoints Diksha Jaswani as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 2/10

MANAGEMENT 📅 17 Sep 2026, 06:39 PM

Alpa Laboratories Limited has announced the appointment of Ms. Diksha Jaswani as the Company Secretary and Compliance Officer (Key Managerial Personnel) effective September 17, 2026. Ms. Jaswani is an associate member of the ICSI (Membership No. A80495) with experience in ROC filings and company law regulatory processes. She holds zero shares in the company and has no relationship with the directors. This appointment ensures regulatory compliance under SEBI Listing Regulations without impacting operational or financial performance.

Appointment of Ms. Diksha Jaswani as Company Secretary cum Compliance Officer effective September 17, 2026
Appointed official holds ICSI Membership No. A80495
Shareholding of the appointee in the company is Nil
Decision approved by the Board of Directors on September 17, 2026

💡 Track upcoming regulatory filings and the upcoming Q2 FY27 earnings release to assess financial execution.

Alpa Laboratories Sets Book Closure from Sep 23 to Sep 30, 2026 for 38th AGM

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Sep 2026, 03:51 PM

Alpa Laboratories Limited has announced the schedule for its 38th Annual General Meeting (AGM), which is set to take place on September 30, 2026, via video conferencing. Pursuant to Section 91 of the Companies Act, 2013, and SEBI Listing Regulations, the Register of Members and Share Transfer Books will be closed from September 23, 2026, to September 30, 2026 (both days inclusive). The record/cut-off date for AGM entitlement is September 22, 2026. This is a standard statutory filing with no direct operational or financial impact.

38th Annual General Meeting scheduled for September 30, 2026, at 14:00 PM IST
Book closure period fixed from September 23, 2026, to September 30, 2026 (both days inclusive)
Record/cut-off date established as September 22, 2026
AGM to be conducted virtually through video conference and audio-visual means

💡 Shareholders looking to participate and vote in the AGM should ensure their shareholdings are credited on or before the September 22, 2026 record date.

Alpa Laboratories Appoints Radhika Biyani as Independent Director Effective Sep 5, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 07 Sep 2026, 03:13 PM

Alpa Laboratories Limited has announced the appointment of Mrs. Radhika Biyani as an Additional Director in the Independent, Non-Executive category effective September 5, 2026. This fills the vacancy created by the cessation of Mrs. Jyoti Jain on July 21, 2026, upon completion of her tenure. The appointment follows the allotment of DIN 11918173 and remains subject to shareholder approval via General Meeting or postal ballot. Concurrently, the company reconstituted its Audit, Nomination and Remuneration, and Stakeholders Relationship committees to ensure SEBI compliance.

Mrs. Radhika Biyani appointed as Independent Non-Executive Director effective September 5, 2026.
Fills vacancy following the completion of Mrs. Jyoti Jain's tenure on July 21, 2026.
Board approval secured on August 13, 2026, with effectiveness pending DIN 11918173 allotment.
Reconstituted key board committees to maintain SEBI LODR compliance.

💡 Track voting outcomes at the upcoming General Meeting or postal ballot for formal shareholder approval of the appointment.

Rs 1.04 Cr Net Profit (Down 91% YoY) as Raw Material Costs Surge to 90% of Revenue

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 13 Aug 2026, 09:06 PM

Alpa Laboratories reported a standalone revenue of Rs 23.93 Cr for Q1 FY27, a 25.2% increase YoY. However, standalone net profit plummeted 91.2% YoY to Rs 1.04 Cr, down from Rs 11.78 Cr in the year-ago period. The profitability was entirely supported by 'Other Income' of Rs 5.83 Cr (including unrealized investment gains), as the company incurred an operating loss of Rs 4.79 Cr due to raw material costs surging to 89.9% of revenue.

Revenue from operations increased 25.2% YoY to Rs 23.93 Cr from Rs 19.11 Cr.
Standalone Net Profit fell 91.2% YoY to Rs 1.04 Cr, heavily reliant on non-operating income.
Cost of materials consumed rose 80.3% YoY to Rs 21.53 Cr, representing 89.9% of revenue.
Other Income of Rs 5.83 Cr includes unrealized profits from fair market value adjustments of investments.
Consolidated Net Profit for the quarter stood lower at Rs 0.98 Cr.

💡 Investors should monitor the sustainability of 'Other Income' and the company's ability to manage raw material costs, which have severely eroded operating margins. Watch for management commentary on pricing power and the impact of government price controls mentioned in previous filings.

Alpa Laboratories Clarifies Board Meeting Date to 13th August 2026

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 11 Aug 2026, 06:01 PM

Alpa Laboratories Limited has issued a clarification regarding its upcoming board meeting. The company corrected a typographical error in a previous filing's subject line which incorrectly stated 14th August 2026. The meeting is officially confirmed to take place on 13th August 2026 at 3:00 PM at the company's registered office. This is a routine administrative correction to ensure accurate scheduling for the upcoming board deliberations.

Corrected Board Meeting date is 13th August 2026
Meeting is scheduled to commence at 3:00 PM
Clarification addresses a typographical error that previously cited 14th August 2026
The meeting will be held at the registered office in Pigdamber, Indore

💡 Investors should look for the outcome of the board meeting on 13th August 2026, which typically includes the disclosure of quarterly financial performance.

Alpa Labs explores expansion into Nigeria via proposed subsidiary Alpa Biopharm Limited

🔵 WATCH ⭐ 5/10

EXPANSION 📅 29 Jul 2026, 06:16 PM

Alpa Laboratories has granted in-principle approval to explore the incorporation of a new overseas entity in Nigeria, tentatively named Alpa Biopharm Limited. The venture is planned in association with Blueseal Pharmaceuticals Limited, Nigeria, to undertake pharmaceutical and healthcare business. As of July 29, 2026, no capital investment has been made, and the shareholding and governance structures are yet to be finalized. This move aligns with the company's strategy to expand its geographic footprint to enhance export revenues, which currently support a TTM revenue of Rs 106 Cr.

In-principle approval granted for exploring an overseas company in the Federal Republic of Nigeria.
Proposed entity to be named 'Alpa Biopharm Limited' in association with Blueseal Pharmaceuticals Limited.
No investment has been made by Alpa Laboratories as of the announcement date, July 29, 2026.
The company reported a TTM revenue of Rs 106 Cr and a Net Worth of Rs 197 Cr, providing a base for future investment capacity.
The move targets international market expansion to mitigate domestic pricing pressures from NPPA controls.

💡 Investors should monitor subsequent filings for the finalized investment amount, shareholding percentage, and the timeline for regulatory approvals in Nigeria.

Alpa Laboratories Submits Revised Q4 FY26 Financial Results Following Exchange Clarification

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 27 Jul 2026, 01:27 PM

Alpa Laboratories Limited has submitted a revised financial filing for the quarter ended March 31, 2026, in response to a clarification sought by the NSE and BSE under Regulation 33 of SEBI LODR. The revised XBRL filing was processed on July 23, 2026, following the exchange's query regarding the initial submission. For the quarter in question, the company had previously reported a revenue of ₹31.4 crore and a net profit of ₹1.38 crore. This action is primarily administrative to ensure compliance with reporting standards.

Revised financial results submitted on July 23, 2026, for the period ended March 31, 2026
Clarification was specifically sought by the Exchange regarding Regulation 33 of SEBI LODR
Company reported a TTM revenue of ₹106 crore and TTM PAT of ₹15 crore as of the March 2026 quarter
The filing was submitted via the NEAPS Integrated Filing- Non-Banking Ind AS Module

💡 Investors should verify if the revised filing contains any material changes to the previously reported net profit of ₹1.38 crore for Q4 FY26, though such revisions are often technical in nature.

Cessation of Ms. Jyoti Jain as Independent Director effective July 21, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 22 Jul 2026, 03:55 PM

Alpa Laboratories Limited has announced that Ms. Jyoti Jain has ceased to be a Non-Executive Independent Director of the company. This change was effective from the close of business hours on July 21, 2026, following the completion of her scheduled tenure. The company, which has a market capitalization of Rs 142 Cr and TTM revenue of Rs 106 Cr, is undergoing a routine board rotation. No other material changes or disagreements were reported in the filing.

Ms. Jyoti Jain ceased to be an Independent Director effective July 21, 2026
The cessation is due to the completion of her tenure as per SEBI regulations
Alpa Laboratories maintains a market capitalization of Rs 142 Cr
The company reported TTM revenue of Rs 106 Cr and TTM PAT of Rs 15 Cr

💡 This is a routine administrative update. Investors should monitor future filings for the appointment of a new independent director to ensure the board remains compliant with SEBI governance norms.

Resignation of Company Secretary and Compliance Officer effective July 26, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 08 Jul 2026, 04:44 PM

Ms. Yashoda Patidar has resigned from her position as Company Secretary and Compliance Officer of Alpa Laboratories Limited, effective July 26, 2026. The resignation was formally tendered on July 8, 2026, citing personal reasons. This is a routine administrative change for the company, which currently operates with a TTM revenue of Rs 106 Cr and a healthy net worth of Rs 197 Cr. The outgoing officer has committed to ensuring a smooth transition of responsibilities during her notice period.

Resignation tendered on July 8, 2026, due to personal reasons.
Cessation of duties effective from the close of business hours on July 26, 2026.
Company reported a TTM PAT of Rs 15 Cr and maintains a very low Debt-to-Equity ratio of 0.01.
The transition period is approximately 18 days from the date of announcement.

💡 Monitor the company's subsequent filings for the appointment of a new Company Secretary to ensure continued compliance with SEBI Listing Obligations.

Alpa Laboratories Announces Trading Window Closure from July 1, 2026, for Q1 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Jun 2026, 02:17 PM

Alpa Laboratories Limited has officially notified the exchanges regarding the closure of its trading window starting July 1, 2026. This measure is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations for the upcoming financial results of the first quarter ending June 30, 2026. The trading window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are declared. This is a standard regulatory procedure followed by listed companies ahead of earnings announcements.

Trading window closure effective from July 1, 2026.
Closure is in relation to the financial results for the quarter ending June 30, 2026.
The window will reopen 48 hours after the official declaration of Q1 results.
Compliance maintained under SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018.

💡 No action is required as this is a routine regulatory filing; investors should monitor the company's upcoming Q1 earnings release for fundamental performance updates.

Alpa Laboratories FY26 Consolidated Net Profit Declines 23% to ₹15.01 Crore

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 29 May 2026, 10:40 PM

Alpa Laboratories Limited reported a decline in its annual financial performance for the year ended March 31, 2026. Consolidated total income fell to ₹121.57 crore from ₹135.80 crore in the previous fiscal year, representing a 10.5% decrease. Net profit for the year dropped by approximately 23% to ₹15.01 crore compared to ₹19.50 crore in FY25. However, the company showed signs of recovery in the final quarter, turning a standalone profit of ₹1.36 crore against a loss of ₹1.95 crore in the same period last year.

Consolidated annual revenue from operations decreased to ₹105.81 crore from ₹112.45 crore in FY25.
Full-year consolidated net profit stood at ₹15.01 crore, down from ₹19.50 crore in the previous year.
Consolidated Earnings Per Share (EPS) declined to ₹7.13 from ₹9.27 year-on-year.
Standalone Q4 FY26 net profit improved to ₹1.36 crore compared to a net loss of ₹1.95 crore in Q4 FY25.
The board appointed M/s S. S. Gandhi & Associates as Internal Auditors and M/s Sudeep Saxena & Associates as Cost Auditors for FY 2026-27.

💡 Investors should monitor the company's declining revenue trend and pressure on annual margins, despite the quarterly turnaround. The stock may face short-term pressure due to the significant year-on-year drop in profitability.

Alpa Laboratories Clarifies No Undisclosed Price Sensitive Info Amid Stock Price Movement

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Apr 2026, 03:24 PM

Alpa Laboratories Limited has issued a formal clarification to the BSE and NSE regarding recent significant movements in its stock price. In its response dated April 9, 2026, the company stated that there is no undisclosed price-sensitive information or pending events that would impact its performance. The management emphasized that all material disclosures have been made in compliance with regulatory requirements. This suggests that the recent volatility in the scrip is likely driven by market sentiment rather than internal corporate developments.

Company responded to Exchange queries dated April 8, 2026, regarding unusual price movement.
Management confirmed no undisclosed events or information are currently pending that would affect stock price.
No upcoming announcements are scheduled that would impact the scrip's price or volume in the near future.
The clarification was issued to both BSE (532878) and NSE (ALPA) to safeguard investor interests.

💡 Investors should treat the recent price volatility as market-driven or speculative since the company has denied any new material developments. It is advised to focus on fundamental performance rather than short-term price fluctuations.

View All ALPA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment of Drugs & Chemicals, which achieved a standalone total income of INR 13,575.71 Lacs in FY 2024-25, representing a growth of 9.82% compared to INR 12,361.28 Lacs in the previous year.

Geographic Revenue Split

Not disclosed in available documents, although the company highlights a strategic focus on expanding export revenues and penetrating new international markets.

Profitability Margins

Profit After Tax (PAT) margin stood at 14.6% for FY 2024-25, with PAT increasing 17.62% YoY to INR 1,982.90 Lacs. Profit Before Tax (PBT) grew by 24.99% to INR 2,584.12 Lacs.

EBITDA Margin

EBITDA margin improved to 20.85% in FY 2024-25 from 18.62% in FY 2023-24, with absolute EBITDA growing 22.99% to INR 2,830.99 Lacs.

Capital Expenditure

Property, plant, and equipment (standalone) was valued at INR 2,105.38 Lacs as of September 30, 2025. Net cash outflow for the purchase of property, plant, and equipment was INR 166.82 Lacs for the half-year ended September 2025.

Credit Rating & Borrowing

The company's bank facilities are rated 'CRISIL B/Stable/CRISIL A4 Issuer Not Cooperating'. Interest charges decreased by 31.60% YoY to INR 26.63 Lacs in FY 2024-25, indicating reduced borrowing costs or debt levels.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) and other key raw materials represent approximately 52% of total income, with costs amounting to INR 7,071.93 Lacs in FY 2024-25.

Import Sources

Not disclosed in available documents; however, the company notes a significant dependence on imported APIs.

Capacity Expansion

Not disclosed in available documents, but the permanent workforce increased by 10.48% to 453 employees in FY 2024-25 to support expanding operations.

Raw Material Costs

Cost of materials consumed was INR 7,071.93 Lacs in FY 2024-25. For the half-year ended September 2025, standalone material costs were INR 2,849.50 Lacs, representing 47.1% of total income for that period.

📈 Strategic Growth

Expected Growth Rate

9.82%

Growth Strategy

Growth will be driven by expanding the geographic footprint in overseas markets to enhance export revenues, investing in R&D for new product launches, and upgrading manufacturing facilities to meet global compliance standards like USFDA and EMA.

Products & Services

The company manufactures a wide range of pharmaceutical products, specifically generic formulations and drugs & chemicals.

Brand Portfolio

Alpa Laboratories.

Market Expansion

Strategic entry into new international markets is identified as a key driver for future topline growth.

🌍 External Factors

Industry Trends

The industry is seeing heightened scrutiny from USFDA, EMA, and WHO. There is a shift toward biotechnology and digital healthcare, requiring companies to adopt new technologies to avoid obsolescence.

Competitive Landscape

Intense competition from domestic players, multinational corporations, and generic manufacturers in both domestic and international markets.

Competitive Moat

Moat is built on WHO-GMP and ISO 9001:2000 certifications and a diversified product portfolio. Sustainability depends on maintaining high compliance standards to differentiate from domestic competitors.

Macro Economic Sensitivity

Highly sensitive to inflation and interest rate fluctuations, which impact operational costs and the 31.60% reduction in interest charges seen in FY25.

Geopolitical Risks

Trade restrictions and changing geopolitical dynamics are cited as risks that may affect exports and overall profitability.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the National Pharmaceutical Pricing Authority (NPPA) for pricing and global bodies like USFDA, EMA, and WHO for manufacturing standards.

Environmental Compliance

The company is subject to environmental regulations and climate-related sustainability mandates, though specific compliance costs are not disclosed.

Taxation Policy Impact

The effective tax rate for FY 2024-25 was approximately 23.8%, with total tax and deferred tax expenses rising 58.13% to INR 616.18 Lacs.

Legal Contingencies

The company has pending litigations disclosed in Note 35 of its financial statements, though management and auditors state these are not expected to have a material impact on the financial position.